New-Onset Heart Failure in the Setting of T4-Conversion Disorder

被引:0
|
作者
Chan, Nicole [1 ]
Pak, Kevin [2 ]
Guo, Alan [3 ]
Singla, Pranav [1 ]
Sayegh, Mark [1 ]
机构
[1] St Johns Riverside Hosp, Internal Med, Yonkers, NY 10701 USA
[2] Lake Erie Coll Osteopath Med, Internal Med, Eerie, PA USA
[3] SUNY Stony Brook, Neurobiol & Behav, Stony Brook, NY 11794 USA
关键词
deiodinase; heart failure with reduced ejection fraction; liothyronine; levo-thyroxine; hypothyroid; THYROID-HORMONE; HYPOTHYROIDISM; LEVOTHYROXINE; DISEASE;
D O I
10.7759/cureus.25024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thyroid hormone is essential in accomplishing the appropriate metabolism of the body. Achieving euthyroidism is of importance due to the deadly ramifications of being hypothyroid, such as multiple organ failure, profound decrease in mentation and even death. We present a case of an 80-year-old female with a history of hypertension, coronary artery disease, chronic kidney disease, hypothyroidism due to total thyroidectomy, and a cerebral vascular accident who presented with slurred speech, decreased appetite, dizziness and lethargy with new-onset weakness. She was adherent to all her medications. Her labs were significant for elevated thyroid-stimulating hormone, elevated free thyroxine, and low total triiodothyronine. Brain MRI revealed no acute pathology. She was given her home dose of Levothyroxine and was admitted to the telemetry unit for evaluation of her symptoms and abnormal thyroid panel. During her hospital course, she was found to have an abnormal rhythm and worsening lethargy. Subsequent electrocardiogram and laboratory values revealed new T-wave inversions and elevated troponin. An echocardiogram revealed a new severely reduced left ventricular function with severe global hypokinesis of the left ventricle and an ejection fraction of 30%. It was only after initiating combination therapy of levothyroxine and liothyronine that her symptoms and abnormal cardiac rhythm resolved. With this careful titration of the patient's medication, we concluded that combination therapy was essential to the patient being euthyroid. This phenomenon was also cited in multiple literature, which warrants an investigation of a certain population's inability to convert T4 to T3. By sharing this case, we aim to aid providers with their differential diagnoses and bring to light a potential area of further investigation. Ultimately, by optimizing and tailoring these medications, we hope to improve their quality of life.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Anemia and new-onset congestive heart failure in the general medicare population
    Sandgren, PE
    Murray, AM
    Herzog, CA
    Solid, CA
    Gilbertson, DT
    Collins, AJ
    Foley, RN
    JOURNAL OF CARDIAC FAILURE, 2005, 11 (02) : 99 - 105
  • [32] Transcriptomic biomarkers for individual risk assessment in new-onset heart failure
    Heidecker, Bettina
    Kasper, Edward K.
    Wittstein, Ilan S.
    Champion, Hunter C.
    Breton, Elayne
    Russell, Stuart D.
    Kittleson, Michelle M.
    Baughman, Kenneth L.
    Hare, Joshua M.
    CIRCULATION, 2008, 118 (03) : 238 - 246
  • [33] Is New-Onset Atrial Fibrillation Bad News for Patients With Heart Failure?
    Iguchi, Moritake
    Akao, Masaharu
    CIRCULATION JOURNAL, 2015, 80 (01) : 62 - 63
  • [34] Estimated pulse wave velocity and risk of new-onset heart failure
    Ji, Chunpeng
    Wang, Guodong
    Huang, Zhe
    Zhu, Chenrui
    Liu, Yan
    ESC HEART FAILURE, 2024, 11 (04): : 2120 - 2128
  • [35] Renoprotective effect of tolvaptan in patients with new-onset acute heart failure
    Kin, Hiromi
    Matsumura, Koichiro
    Yamamoto, Yoshihiro
    Fujii, Kenichi
    Otagaki, Munemitsu
    Takahashi, Hiroki
    Park, Haengnam
    Yoshioka, Kei
    Yokoi, Mitsuru
    Sugiura, Tetsuro
    Shiojima, Ichiro
    ESC HEART FAILURE, 2020, 7 (04): : 1764 - 1770
  • [36] Proenkephalin and the risk of new-onset heart failure: data from PREVEND
    Emmens, J. E.
    Ter Maaten, J. M.
    Brouwers, F. P.
    Kieneker, L. M.
    Damman, K.
    Hartmann, O.
    Schulte, J.
    Bakker, S. J. L.
    De Boer, R. A.
    Voors, A. A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 164 - 165
  • [37] Timely Management of New-Onset Heart Failure The Other Vulnerable Phase
    Gracia, Ely
    Hamid, Arsalan
    Butler, Javed
    CIRCULATION, 2019, 140 (08) : 621 - 623
  • [38] Ischemic Evaluation in New-Onset Methamphetamine-Associated Heart Failure
    Kersey, Cooper B.
    Hidano, Danelle
    Chiang, Joey
    Doshi, Shradha
    Longenecker, Chris T.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (22):
  • [39] Dapagliflozin effect on heart failure with prevalent or new-onset atrial fibrillation
    Arita, Vicente Artola
    Van Veldhuisen, Dirk J.
    Rienstra, Michiel
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (03) : 526 - 528
  • [40] Prognostic Impact and Predictors of New-Onset Atrial Fibrillation in Heart Failure
    Choi, Hyo-In
    Lee, Sang Eun
    Kim, Min-Seok
    Lee, Hae-Young
    Cho, Hyun-Jai
    Choi, Jin Oh
    Jeon, Eun-Seok
    Hwang, Kyung-Kuk
    Chae, Shung Chull
    Baek, Sang Hong
    Kang, Seok-Min
    Choi, Dong-Ju
    Yoo, Byung-Su
    Kim, Kye Hun
    Cho, Myeong-Chan
    Oh, Byung-Hee
    Kim, Jae-Joong
    LIFE-BASEL, 2022, 12 (04):